230 related articles for article (PubMed ID: 22245905)
41. Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.
Giannelli G; Santoro A; Kelley RK; Gane E; Paradis V; Cleverly A; Smith C; Estrem ST; Man M; Wang S; Lahn MM; Raymond E; Benhadji KA; Faivre S
PLoS One; 2020; 15(3):e0222259. PubMed ID: 32210440
[TBL] [Abstract][Full Text] [Related]
42. The prognostic utility of baseline alpha-fetoprotein for hepatocellular carcinoma patients.
Silva JP; Gorman RA; Berger NG; Tsai S; Christians KK; Clarke CN; Mogal H; Gamblin TC
J Surg Oncol; 2017 Dec; 116(7):831-840. PubMed ID: 28743160
[TBL] [Abstract][Full Text] [Related]
43. AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma.
Yaprak O; Akyildiz M; Dayangac M; Demirbas BT; Guler N; Dogusoy GB; Yuzer Y; Tokat Y
Hepatobiliary Pancreat Dis Int; 2012 Jun; 11(3):256-61. PubMed ID: 22672818
[TBL] [Abstract][Full Text] [Related]
44. Alpha-fetoprotein response following transarterial chemoembolization indicates improved survival for intermediate-stage hepatocellular carcinoma.
Liu G; Ouyang Q; Xia F; Fan G; Yu J; Zhang C; Wang D
HPB (Oxford); 2019 Jan; 21(1):107-113. PubMed ID: 30017783
[TBL] [Abstract][Full Text] [Related]
45. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.
Mazzaferro V; Sposito C; Zhou J; Pinna AD; De Carlis L; Fan J; Cescon M; Di Sandro S; Yi-Feng H; Lauterio A; Bongini M; Cucchetti A
Gastroenterology; 2018 Jan; 154(1):128-139. PubMed ID: 28989060
[TBL] [Abstract][Full Text] [Related]
46. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
Ann Oncol; 2013 Apr; 24(4):965-73. PubMed ID: 23223331
[TBL] [Abstract][Full Text] [Related]
47. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
[TBL] [Abstract][Full Text] [Related]
48. Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma.
Li P; Wang SS; Liu H; Li N; McNutt MA; Li G; Ding HG
World J Gastroenterol; 2011 Nov; 17(41):4563-71. PubMed ID: 22147961
[TBL] [Abstract][Full Text] [Related]
49. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
Wang W; Bai W; Wang E; Zhao Y; Liu L; Yang M; Cai H; Xia D; Zhang L; Niu J; Yin Z; Zhang Z; Fan D; Xia J; Han G
Int J Cancer; 2017 Jan; 140(2):390-399. PubMed ID: 27681592
[TBL] [Abstract][Full Text] [Related]
50. Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma.
Dettmer A; Kirchhoff TD; Gebel M; Zender L; Malek NP; Panning B; Chavan A; Rosenthal H; Kubicka S; Krusche S; Merkesdal S; Galanski M; Manns MP; Bleck JS
World J Gastroenterol; 2006 Jun; 12(23):3707-15. PubMed ID: 16773687
[TBL] [Abstract][Full Text] [Related]
51. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.
Riaz A; Miller FH; Kulik LM; Nikolaidis P; Yaghmai V; Lewandowski RJ; Mulcahy MF; Ryu RK; Sato KT; Gupta R; Wang E; Baker T; Abecassis M; Benson AB; Nemcek AA; Omary R; Salem R
JAMA; 2010 Mar; 303(11):1062-9. PubMed ID: 20233824
[TBL] [Abstract][Full Text] [Related]
52. Changes of serum alpha-fetoprotein and alpha-fetoprotein-L3 after hepatectomy for hepatocellular carcinoma: prognostic significance.
Zhang XF; Yin ZF; Wang K; Zhang ZQ; Qian HH; Shi LH
Hepatobiliary Pancreat Dis Int; 2012 Dec; 11(6):618-23. PubMed ID: 23232633
[TBL] [Abstract][Full Text] [Related]
53. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.
Bonekamp S; Halappa VG; Geschwind JF; Li Z; Corona-Villalobos CP; Reyes D; Bhagat N; Cosgrove DP; Pawlik TM; Mezey E; Eng J; Kamel IR
Radiology; 2013 Aug; 268(2):431-9. PubMed ID: 23616632
[TBL] [Abstract][Full Text] [Related]
54. Initial Alpha-Fetoprotein Response Predicts Prognosis in Hepatitis B-related Solitary HCC Patients After Radiofrequency Ablation.
Yu SJ; Kwon JH; Kim W; Yoon JH; Lee JM; Lee JY; Cho EJ; Lee JH; Kim HY; Jung YJ; Kim YJ
J Clin Gastroenterol; 2018 Mar; 52(3):e18-e26. PubMed ID: 28795996
[TBL] [Abstract][Full Text] [Related]
55. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor.
Vitale A; Farinati F; Burra P; Trevisani F; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Sacco R; Morisco F; Missale G; Foschi FG; Gasbarrini A; Svegliati Baroni G; Virdone R; Chiaramonte M; Spolverato G; Cillo U;
Liver Transpl; 2015 Oct; 21(10):1250-8. PubMed ID: 26183802
[TBL] [Abstract][Full Text] [Related]
56. The tumor marker score is an independent predictor of survival in patients with recurrent hepatocellular carcinoma.
Okamura Y; Ashida R; Ito T; Sugiura T; Mori K; Uesaka K
Surg Today; 2015 Dec; 45(12):1513-20. PubMed ID: 25527455
[TBL] [Abstract][Full Text] [Related]
57. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation.
Kim BK; Kim KA; Park JY; Ahn SH; Chon CY; Han KH; Kim SU; Kim MJ
Eur J Cancer; 2013 Mar; 49(4):826-34. PubMed ID: 22995582
[TBL] [Abstract][Full Text] [Related]
58. Diagnostic value of alpha-1-fetoprotein (AFP) as a biomarker for hepatocellular carcinoma recurrence after liver transplantation.
Nörthen A; Asendorf T; Walson PD; Oellerich M
Clin Biochem; 2018 Feb; 52():20-25. PubMed ID: 29054441
[TBL] [Abstract][Full Text] [Related]
59. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
[TBL] [Abstract][Full Text] [Related]
60. EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.
Liu L; Wang W; Chen H; Zhao Y; Bai W; Yin Z; He C; Jia J; Yang M; Xia J; Fan D; Han G
Clin Cancer Res; 2014 Mar; 20(6):1623-31. PubMed ID: 24493832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
